Overview

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Treatments:

Fluorouracil
Irinotecan
Leucovorin
magrolimab
Nivolumab
Oxaliplatin